Clinical and laboratory status of patients with chronic chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue 8, 2009, Pages 1139-1147

  de Lana, Marta ^a   Lopes, Leonardo A ^b   Martins, Helen R ^b   Bahia, Maria T ^c   Machado de Assis, Girley F ^b   Wendling, Ana P ^d   Martins Filho, Olindo A ^d   Montoya, Roberto A ^e   Dias, João C P ^d   Albajar Viñas, Pedro ^d   Coura, José R ^d  

^a Escola de Farmacia   (Brazil)

^b Núcleo de Pesquisas em Ciências Biológicas   (Brazil)

^c FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e Unidade Técnica de Doenças Transmissíveis e Análise de Situação em Saúde   (Brazil)

Author keywords

Aetiological treatment; Benznidazole; Chagas disease; Clinical evolution; Clinical laboratorial evaluation

Indexed keywords

EID: 72449122855     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/s0074-02762009000800011     Document Type: Article

References (44)

1. Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM 1996. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348: 1407-1413.
2. Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA 1991. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi under specific chemotherapy. Mem Inst Oswaldo Cruz 86: 187-200.
3. Anonymous 2005. Consenso Brasileiro em Doença de Chagas. Rev Soc Bras Med Trop 38: 5-26.
4. Bahia MT, Guedes PMM, Fietto JLR, Lana M, Toledo MJO 2005. Current advance in human and experimental Chagas disease chemotherapy. In RM Mohan, Global research network (Org.) research advances in antimicrobial agents and chemoterapy, Kerala, p. 99-121.
5. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC 2008. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 299: 1134-1135.
6. Braga MS, Lauria-Pires L, Arganaraz ER, Nascimento RJ, Teixeira AR 2000. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop Sao Paulo 42: 157-161.
7. Britto C, Silveira C, Cardoso MA, Marques P, Luquetti A, Macedo V, Fernandes O 2001. Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polimerase chain reaction. Mem Inst Oswaldo Cruz 96: 823-826.
8. Britto CC 2009. Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Mem Inst Oswaldo Cruz 104 (Suppl. 1): 122-135.
9. Cançado JR 1997. Terapêutica específica. In JCP Dias, JR Coura, Clínica e terapêutica da doença de Chagas. Uma abordagem prática para o clínico geral, Ed. Fiocruz, Rio de Janeiro, p. 323-351.
10. Cançado JR 2002. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44: 29-37.
11. Castro AM, Luquetti AO, Rass A 2002. Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi. Parasitol Res 88: 894-900.
12. Chiari E, Dias JCP, Lana M, Chiari CA 1989. Hemoculture for the parasitological diagnosis of humam cronic Chagas disease. Rev Soc Bras Med Trop 22: 19-23.
13. Cordeiro FD, Martins-Filho OA, da Costa Rocha MO, Adad SJ, Correa-Oliveira R, Romanha AJ 2001. Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease. Clin Diag Labor Immunol 8: 112-118.
14. Coura JR 2009. Present situation and new strategies for Chagas disease chemotherapy: a proposal. Mem Inst Oswaldo Cruz 104: 549-554.
15. Coura JR, Abreu LL, Wilcox F, Petana W 1997. Estudo comparativo com emprego de benznidazole, nifurtimox e placebo na forma crônica da doença de Chagas em área de campo com transmissão interrompida. Rev Soc Bras Med Trop 30: 139-144.
16. Coura JR, Castro SL 2002. A critical review on Chagas Disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.
17. Dias JCP 2002. O controle da doença de Chagas no Brasil. In AC Silveira. O controle da doença de Chagas nos países do Cone Sul da América, Faculdade de Medicina de Triângulo Mineiro, Uberaba, p. 145-239.
18. Dias JCP 2006. The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med 144: 772-774.
19. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA 2007. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina) over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40: 1-10.
20. Gallerano RR, Sosa RR 2000. Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy. Rev Fac Cien Med Univ Nac Cordoba 57: 135-162.
21. Galvão LMC, Chiari E, Macedo AM, Luquetti AO, Silva AS, Andrade ALS 2003. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J Clin Microbiol 41: 5066-5070.
22. Gomes ML, Macedo AM, Vago AR, Pena SDJ, Galvão LMC, Chiari E 1998. Trypanosoma cruzi: Optimization of polymerase chain reaction for detection in human blood. Exp Parasitol 88: 28-33.
23. Ianni BM, Mady C 1998. Therapeutics for the chronic form of Chagas' disease. Is the etiological treatment effective? Arq Bras Cardiol 70: 59-61.
24. Krettli AU, Brener Z 1982. Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. J Immunol 128: 2009-2012.
25. Lauria-Pires L, Braga M, Vexenat AC, Nitz N, Simoes-Barbosa A, Tinoco DL, Teixeira AR 2000. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 63: 111-118.
26. Luquetti A, Rassi A 1998. Tratamiento de la enfermedad de Chagas en fase crônica: Critérios de cura convencionales: xenodiagnóstico, hemocultivo y serologia. Rev Patol Trop 27: 37-51.
27. Macedo V, Silveira CA 1987. Perspectiva da terapêutica específica da doença de Chagas. Experiências na forma indeterminada. Rev Soc Bras Med Trop 20: M24-M26.
28. Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A 2009. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 104: 319-324.
29. Martins HR, Figueiredo LM, Valamiel-Silva JC, Carneiro CM, Machado-Coelho GL, Vitelli-Avelar DM, Bahia MT, Martins-Filho OA, Macedo AM, Lana M 2008. Persistence of PCRpositive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes. J Antimicrob Chemother 61: 1319-1327.
30. Martins-Filho OA, Pereira ME, Carvalho JF, Cançado JR, Brener Z 1995. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Clin Diag Lab Immunol 2: 569-573.
31. Montoya RA 1998. Morbidade da doença de Chagas no município de Berilo, Minas Gerais, Brasil. Estudos seccional e longitudinal da cardiopatia chagásica crônica (1987-1997), PhD Thesis, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, 153 pp.
32. OMS/OPAS - Organización Mundial de la Salud/Organización Panamericana de la Salud 1974. Aspectos clínicos de la enfermedad de Chagas. Informe de una reunión conjunta OMS/OPS de investigadores. Boll Ofic Sanit Panam 76: 141-158.
33. Prata A 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92-100.
34. Resende JM, Lauar KL, Oliveira AR 1960. Aspectos clínicos e radiológicos da aperistalsis do esôfago. Rev Bras Gastroenterol 12: 247-262.
35. Reyes PA, Vallejo M. 2005. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev 19: CD004102.
36. Segura MA, Mollina de Aspi E, Basombria MA 1994. Reversibility of muscle and heart lesions in chronic Trypanosoma cruzi infected mice after late tripanosomicidal treatment. Mem Inst Oswaldo Cruz 89: 213-216.
37. Sosa-Estani S, Segura EL 2006. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 19: 583-587.
38. Streiger ML, Del Barco ML, Fabbro DL, Arias, ED, Amicone NA 2004. Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina. Rev Soc Bras Med Trop 37: 365-375.
39. Suasnábar SA, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, Amicone N 2000. Evolutive behavior towards cardiomyopathy of treated (nirfurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 42: 99-109.
40. Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S. 2002. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 1: CD003463.
41. Viotti R, Vigliano C, Armenti H, Segura E 1994. Treatment of chronic Chagas' disease with benznidazolee: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127: 151-162.
42. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724-734.
43. Voller A, Bidwell DE, Bartlett A 1976. Enzyme immunoassays in diagnostic medicine. Theory and practice. Bull WHO 53: 55-65.
44. WHO 2005. Report of the cientific working group on Chagas disease Chagas disease. Available from: http://www.who.int/tdr/diseases/chagas/swg_chagas.htm.